GlassScriptPhysician profile
Sarah Byrd
NPI 1982057527
$3,700.91
in general payments reported to CMS, 2019-2025
21 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $463 · 2022: $645 · 2023: $1,088 · 2024: $1,028 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138 · Education: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.23 |
| Education | $453.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $950.43 | 2021-2025 | Tremfya |
| Abbvie INC. | $779.46 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $303.39 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $229.53 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $216.43 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $192.52 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $142.37 | 2022-2025 | Absorica Ld, Winlevi |
| Ucb, INC. | $138.59 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $137.56 | 2022-2025 | Opzelura |
| Organogenesis INC. | $132.05 | 2024 | |
| Leo Pharma INC. | $106.96 | 2021-2024 | Adbry |
| Arcutis Biotherapeutics, INC. | $106.21 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $56.33 | 2023 | Vtama |
| Amgen INC. | $41.85 | 2023-2024 | Otezla |
| Pfizer INC. | $40.28 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $26.50 | 2025 | Rexulti |
| Genzyme Corporation | $24.96 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.01 | 2025 | |
| Novo Nordisk INC | $18.82 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $18.31 | 2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $16.35 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.